No impact of increasing symptoms on quality of life? Longitudinal data from the German MALIFE-Project on patients receiving monochemo- and endocrine treatment for advanced breast cancer – results from the TMK registry group. 7. Juni 2015 Marschner, N., Nusch, A., Decker, T., Münz, M., Kruggel, L., Jänicke, M., 2015. The Breast 24 (suppl3) (OR51), 39. doi:10.1016/S0960-9776(15)30063-1 Abstract No impact of increasing symptom burden on quality of life? – Longitudinal data from the German MaLife-Project on patients receiving monochemo- and endocrine treatment for metastatic breast cancer. Marschner, N., Nusch, A., Decker, T., Münz, M., Kruggel, L., Jänicke, M., 2015. Oncol Res Treat 38 (suppl 5)(V670), 202. doi:10.1159/00043907… Weiterlesen Preliminary safety and efficacy results from the multicentre OTILIA observational study of bevacizumab-containing therapy in women with newly diagnosed ovarian cancer in Germany. Mustea, A., Oskay-Oezcelik, G., Wimberger, P., Reichert, D., Forstbauer, H., Keller, M., Frank, M., Klawitter, S., Kiewitz, C., Mueller, M., Sehouli, J., 2015. European Journal… Weiterlesen